PubMed Health⌕ Search

Biomedical subjects

Sridhar Shankar

Publications and source records attributed to Sridhar Shankar.

At least 19 recordsLinked to original sources
PubMed2006

Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session.

Percutaneous computed tomography (CT)-guided radiofrequency (RF) ablation has been used in the palliative treatment of symptomatic bilateral adrenal tumors, often with each tumor addressed separately over the course of multiple treatment sessions. In the present case, a 71-year-old man with a diagnosis of lung cancer and painful bilateral metastases to the adrenal glands underwent percutaneous CT-guided RF thermal ablation of both adrenal masses in a single session (left adrenal mass, 4.7 cm; right adrenal mass, 4.3 cm), without occurrence of blood pressure instability or other acute complications. Measurement of plasma levels of cortisol, adrenocorticotropic hormone (ACTH), and glucose before and after RF ablation revealed transient changes that suggested preservation of endocrine feedback mechanisms. The patient experienced marked relief in pain bilaterally. By 5 days after the procedure, cortisol, ACTH, and glucose levels returned to preprocedural levels. On further follow-up at 6 months, the patient noted a lack of endocrine sequelae and continued pain relief.

Adenocarcinoma↗
PubMed2005

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.

PURPOSE: To determine the clinical, pathologic, and molecular effects of neoadjuvant docetaxel chemotherapy in high-risk localized prostate cancer. EXPERIMENTAL DESIGN: Patients with biopsy Gleason scores of 8 to 10, serum prostate-specific antigen levels >20 ng/mL, and/or clinical stage T3 disease received weekly docetaxel (36 mg/m2) for 6 months, followed by radical prostatectomy, and were monitored with weekly visits, serum prostate-specific antigen measurements, and endorectal magnetic resonance imaging (MRI). Frozen tumor specimens were collected for microarray analysis. RESULTS: The 19 patients enrolled received 82% of the planned chemotherapy. Toxicity was mild to moderate; fatigue and taste disturbance were common. Prostate-specific antigen declines of >50% were seen in 11 of 19 patients (58%; 95% confidence interval, 33-80%) and endorectal MRI showed maximum tumor volume reduction of at least 25% in 13 of 19 patients (68%; 95% confidence interval, 47-85%) and at least 50% in 4 patients (21%; 95% confidence interval, 6-46%). Sixteen patients completed chemotherapy and had radical prostatectomy; none achieved pathologic complete response. Microarray analysis identified coordinate up-regulation of genes involved in androgen metabolism associated with docetaxel therapy. Specifically, RNA expression for genes that decrease cellular levels of bioactive androgens was coordinately increased in response to chemotherapy. CONCLUSIONS: Neoadjuvant docetaxel administered for 6 months before radical prostatectomy is feasible, well tolerated, and often results in prostate-specific antigen declines of >50% and decreased tumor volume on endorectal MRI. No pathologic complete responses were observed. Altered androgen metabolism may partially account for the noted declines in prostate-specific antigen and be a mechanism for chemotherapy resistance.

Adult↗
PubMed2005

Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.

PURPOSE: To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial response to imatinib mesylate. MATERIALS AND METHODS: Ninety-two patients with metastatic GIST who underwent treatment in a clinical trial with oral imatinib mesylate were followed up for 29 months. An institutional review board-approved protocol was used. The study complied with the Health Insurance Portability and Accountability Act, and written informed consent was obtained from all patients. Images of the chest, abdomen, and pelvis, acquired with computed tomography (CT), positron emission tomography (PET), and, in some cases, magnetic resonance imaging, were evaluated for treatment response and disease recurrence. Thirty-nine patients (29 men, 10 women; age range, 18-84 years; mean, 49.2 years) had recurrent disease after an initial variable period of response (range, 2-24 months; median, 14.4 months). Initial response was determined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumor, and decreased attenuation at CT. Images were evaluated for disease recurrence by two experienced radiologists who were blinded to each other's interpretation but not to clinical details. Final reading was performed by consensus. RESULTS: A nodule within a mass was seen in 21 of 39 patients (in intrahepatic tumor [n = 8], extrahepatic tumor [n = 10], or both intra- and extrahepatic tumors [n = 3]) and was the first sign of disease progression in 17 of 21 patients. Other patterns of recurrence included new site of disease (n = 7), regrowth of preexistent lesion (n = 20), and mixed (more than one) pattern (n = 9). Disease progression was verified at needle biopsy (n = 16), follow-up imaging (n = 14), and/or surgical resection (n = 9). CONCLUSION: A nodule within a mass is an important sign of recurrent GIST, but measurements of overall tumor size may not enable detection of such nodules.

Adolescent↗
PubMed2005

Renal tumors: MR imaging-guided percutaneous cryotherapy--initial experience in 23 patients.

PURPOSE: To evaluate the initial clinical experience of magnetic resonance (MR) imaging-guided percutaneous cryotherapy of renal tumors. MATERIALS AND METHODS: Twenty-six renal tumors (diameter range, 1.0-4.6 cm; mean, 2.6 cm) in 23 patients were treated with 27 cryoablation procedures by using a protocol approved by the human subjects committee at the authors' institution. The study complied with the Health Insurance Portability and Accountability Act. Written informed consent was obtained from each patient. There were 17 men and six women with an average age of 66 years (range, 43-86 years). Of 26 masses, 24 were renal cell carcinoma, one was a transitional cell carcinoma, and one was an angiomyolipoma. By using a 0.5-T open MR imaging system and general anesthesia in patients, one to five (mean, 2.4) needlelike cryoprobes were placed and lesions were ablated by using real-time MR imaging for intraprocedural monitoring of ice balls. Tumors were considered successfully ablated if they demonstrated no contrast enhancement at follow-up computed tomography or MR imaging (mean, 14 months; range, 4-30 months). RESULTS: Twenty-four of 26 tumors were successfully ablated, 23 of which required only one treatment session. Two complications occurred in a total of 27 cryoablations: one hemorrhage, which required a blood transfusion, and one abscess, which was treated successfully with percutaneous catheter drainage. CONCLUSION: MR imaging-guided percutaneous cryotherapy of renal tumors shows promise for the treatment of selected small renal tumors, and MR imaging can be used to monitor the treatment intraprocedurally. This technique may prove useful for ablation of renal tumors completely in one session, but long-term follow-up is needed.

Adult↗
PubMed2005

Radiofrequency ablation of liver tumors: a new cause of benign portal venous gas.

PURPOSE: To retrospectively describe and categorize the presence of portal venous gas (PVG) from radiofrequency (RF) ablation of hepatic tumors. MATERIALS AND METHODS: The study was HIPAA compliant, and informed consent was waived. Thirty-four consecutive computed tomography (CT)-guided percutaneous RF ablations of liver tumors in 26 patients (13 men, 13 women; mean age, 69 years) with five hepatocellular carcinomas and 21 metastatic liver tumors (13 colon, five other, and three unknown primary tumors) were performed with an institutional review board-approved protocol. Two treatment modalities were used: RF ablation alone (13 procedures) and combined RF ablation and ethanol injection (21 procedures). Presence of PVG was quantified with three parameters: maximum length of a portal venous branch with gas, number of Couinaud segments in which PVG was seen, and total number of portal venous branch points with gas. Then an overall PVG score from 0 to 5 was determined. Also, when tumoral gas was seen on CT scans, the largest cross-sectional area of gas was measured. The two ablation methods were compared for quantities of PVG and tumoral gas. The role of N(2)O anesthetic in PVG and tumoral gas formation during ablation also was studied. Statistical analyses were performed with Wilcoxon rank sum and Student t tests. RESULTS: In 25 procedures (74%), gas was found in portal vein branches; in 30 procedures (88%), gas was also found in tumoral and peritumoral tissues. There was no significant difference in frequency of PVG between the ablation methods. Combined therapy yielded significantly greater lengths of PVG (P < .002) and more portal venous branch points (P < .001) than did RF ablation alone. Mean PVG score was 2.4 +/- 0.4 (standard error of the mean) for combined therapy and 0.9 +/- 0.2 for RF ablation alone (P < .004). N(2)O anesthetic was associated with greater amounts of tumoral gas (P < .008) and PVG (P < .03). Tumoral gas, peritumoral gas, and PVG dissipated within 20 minutes after ablation in all patients. No morbidity or mortality was associated with PVG. CONCLUSION: RF ablation is a common yet benign cause of transient PVG, tumoral gas, and peritumoral gas. Combined RF and ethanol ablation was associated with more PVG than was RF ablation alone.

Aged↗
PubMed2005

Radiofrequency ablation of thoracic lesions: part 1, experiments in the normal porcine thorax.

OBJECTIVE: Radiofrequency ablation has been used extensively in the liver for the localized thermal coagulation of tumors. It has been applied more recently percutaneously in the lung under CT imaging guidance. In advance of our own clinical application, we performed experimental percutaneous radiofrequency ablation in normal lung tissues in a large animal model using a U.S. Food and Drug Administration-approved device to assess its use. MATERIALS AND METHODS: Radiofrequency ablation of 22 thoracic sites was performed in vivo in three pigs with an array-style electrode. Tissue impedance and ablation duration were measured for each site. The intact lungs were excised for gross inspection and for imaging with CT and MRI. Representative lesions were evaluated histologically. RESULTS: The mean intraprocedural tissue impedance was 93 Ohms (range, 52-184 Ohms). Six of 22 ablations exhibited a marked increase in impedance after 5 min of treatment. On gross inspection, parenchymal lesions were generally round and targetlike in appearance. CT showed sites of ablation to be composed of a heterogeneous inner zone surrounded by a high-density outer zone. On MRI, the inner zone was typically hyperintense on T1-weighted fast spin-echo imaging, and the outer zone was hyperintense on T2-weighted fast spin-echo imaging. At histology, the inner zone was characterized by coagulation necrosis, and the outer zone by hyperemia and edema. No acute lung-specific complications were seen. There was one extensive skin burn and one cardiac-related death. CONCLUSION: These results support current seminal clinical evidence that percutaneous radiofrequency ablation in the lung is feasible and can be applied safely. Radiofrequency-induced lesions in the normal porcine lung can be visualized with both CT and MRI; image appearance is concordant with histologic tissue changes.

Animals↗
PubMed2005

Radiofrequency ablation of thoracic lesions: part 2, initial clinical experience--technical and multidisciplinary considerations in 30 patients.

OBJECTIVE: The purpose of our study was to report our initial experience with patients who underwent percutaneous imaging-guided radiofrequency ablation of thoracic lesions, and to emphasize technical and multidisciplinary issues and adjunctive procedures specific to thoracic tumor ablation. MATERIALS AND METHODS: Our cohort consisted of 30 patients with a spectrum of primary (n=18) and secondary (n=11) lung tumors, mesothelioma (n=1), and five secondarily eroded, painful ribs who underwent ablation of 36 total lesions (one patient had two ablations). Patients either were nonsurgical candidates because of medical comorbidities or extent of disease, or had exhausted chemotherapy and radiation therapy options, or had refused surgery or undergone unsuccessful surgery. Patients were treated with radiofrequency ablation after agreement among oncologists, thoracic surgeons, and interventional radiologists. An array-style electrode under impedance control was used to treat 29 thoracic tumors and the adjacent rib metastases (n=5). A cool-tip radiofrequency probe was used for two patients. CT guidance and general anesthetic were used for all but one patient. Sonographic guidance and IV conscious sedation were used in one patient. Pain (n=11) and tumor cure or control (n=19) were the primary indications for the procedures. Adjunctive procedures to the radiofrequency ablations included the creation of saline or water windows (n=3); establishment of transosseous and transchondral routes (n=4); use of intercostal and paravertebral nerve blocks (n=15); and use of an intraprocedural catheter (n=1), needle (n=1), or sheath (n=3) for treatment of pneumothoraces. Follow-up was from 2 to 26 months. RESULTS: All ablations were technically successful. No periprocedural mortality occurred. Necrosis of tumor was greater than 90% in 26 of 30 lesions based on short-term follow-up imaging (CT, PET, MRI). In the 11 patients who underwent ablation for pain, relief was complete in four and partial in the other seven. One patient developed a local skin burn, four patients had self-limited hemoptysis up to 4 days after ablation, one had transient atrial fibrillation, one developed hoarseness, and two patients were transiently reintubated after extubation. Eight pneumothoraces developed; one patient underwent placement of a chest tube. Four patients died within 1 year of ablation from extrathoracic spread of tumor. CONCLUSION: Radiofrequency ablation for a variety of thoracic tumors can be performed safely and with a high degree of efficacy for pain control and tumor killing. The effect of ablation can be assessed with CT, MRI, or PET. Various technical issues differentiate thoracic tumor ablation from standard abdominal ablations. Numerous other thoracic interventional radiology procedures are beneficial to assist the radiofrequency ablation. A multidisciplinary approach offers valuable expertise for patient care.

Adult↗
PubMed2004

Imaging and percutaneous management of acute complicated pancreatitis.

Acute pancreatitis varies from a mild, self-limited disease to one with significant morbidity and mortality in its most severe forms. While clinical criteria abound, imaging has become indispensable to diagnose the extent of the disease and its complications, as well as to guide and monitor therapy. Percutaneous interventional techniques offer options that can be life-saving, surgery-sparing or important adjuncts to operation. Close cooperation and communication between the surgeon, gastroenterologist and interventional radiologist enhance the likelihood of successful patient care.

Abscess↗
PubMed2004

Evaluation of patients referred for percutaneous ablation of renal tumors: importance of a preprocedural diagnosis.

OBJECTIVE: Percutaneous ablation of renal cell carcinoma has the potential to be as effective as partial nephrectomy. Because the entire tumor cannot be examined at pathology, diagnosis relies solely on imaging and percutaneous biopsy. Diagnoses of cancer have been rendered using imaging alone in some clinical trials of percutaneous ablation. If these trials inadvertently included benign masses, the efficacy of ablation was overestimated. Therefore, we sought to determine the prevalence of benign masses in a population of patients referred for percutaneous tumor ablation of presumed renal cell carcinoma. SUBJECTS AND METHODS: Twenty-seven patients were referred by urologists for MRI-guided cryotherapy of suspected renal cell carcinoma. Renal masses ranged from 1.0 to 4.6 cm (mean, 2.2 cm) in diameter. The CT, MRI, and percutaneous biopsy findings were tabulated and compared with surgical and imaging follow-up. RESULTS: Ten patients (37%) had a benign renal mass, including three angiomyolipomas, that had no evidence of fat on CT or MRI. Three masses were proven benign by biopsy, three by imaging, and four by a combination of biopsy and imaging. The masses in the remaining 17 patients were ablated. Biopsy revealed malignant cells in 10, suspicious cells in four, and atypical cells in two; one was nondiagnostic. CONCLUSION: A substantial percentage of patients referred for percutaneous ablation of renal tumors had benign masses. If CT or MRI alone cannot be used to diagnose a benign entity, patients should undergo a biopsy before the treatment session.

Adult↗
PubMed2004

Three-dimensional assessment of MRI-guided percutaneous cryotherapy of liver metastases.

OBJECTIVE: We report our initial investigation of the use of a 3D method for assessing percutaneous tumor ablations. We hypothesized that these 3D techniques could be used to assess the technical success of ablations and that 3D metrics would be predictive of treatment response. CONCLUSION: Three-dimensional assessment of percutaneous tumor ablations provides a quantitative evaluation of the technical success of the procedure. Three-dimensional computer-based techniques can both quantify coverage of a tumor and create a virtual ablation margin for percutaneous procedures, akin to a surgical margin. Although results are preliminary, 3D metrics were useful in predicting treatment response.

Aged↗
PubMed2004

Combined radiofrequency and alcohol injection for percutaneous hepatic tumor ablation.

OBJECTIVE: We sought to determine if alcohol potentiates radiofrequency energy by obtaining larger ablative volumes in 30 liver tumors in human patients. SUBJECTS AND METHODS: We compared two groups of patients: one group treated with radiofrequency ablation alone (radiofrequency-alone group), and a second group treated with radiofrequency ablation and immediate prior injection of alcohol (combined group). The radiofrequency-alone group comprised 20 ablations (mean diameter, 8.4 cm; colorectal cancer metastases [n = 15]; other metastases [n = 5]). The combined group consisted of 30 radiofrequency ablations (mean diameter, 8.8 cm; metastatic colorectal cancer [n = 17]; other metastases [n = 8]; and hepatocellular carcinoma [n = 5]) treated with alcohol injection immediately before radiofrequency ablation. The amount of alcohol injected was determined by the size and location of tumors. Preprocedural laboratory tests (complete blood cell count with differential, liver function tests, and coagulation parameters) were performed in all patients, along with pre- and postprocedural CT, MRI, and PET. Measurements of tissue necrosis were obtained on the postprocedural CT scans and MR images. Volumes of necrosis calculated in each group were corrected for the number of radiofrequency applications and were statistically compared using the Student's t test. In addition, tissue impedances obtained during the radiofrequency ablation procedure were compared between the two groups. RESULTS: The mean ablation volumes for the radiofrequency-alone group were 32.3 cm(2) (median, 28.6 cm(2); range, 14.4-61.8 cm(2)) and for the combined group, 84.6 cm(2) (median, 78.3 cm(2); range, 34.6-149 cm(2)). The difference in the necrosis volumes was significantly larger (p < 0.0001) in the combined group. Overall, the combined treatment group underwent fewer radiofrequency applications per session. Tissue impedance during radiofrequency ablation was higher in the combined group (mean, 62.7 vs 57.3 Omega in the radiofrequency alone group; p = 0.0005) at comparable times during the ablations. No major complications were seen in either group. CONCLUSION: Percutaneous radiofrequency ablation appears to be potentiated by immediate prior alcohol injection into the tumor. Consistently larger lesions are obtainable in fewer sessions, without any increase of complications, using the combined method.

Aged↗
PubMed2003

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

A large number of cancer-associated gene products evoke immune recognition, but host reactions rarely impede disease progression. The weak immunogenicity of nascent tumors contributes to this failure in host defense. Therapeutic vaccines that enhance dendritic cell presentation of cancer antigens increase specific cellular and humoral responses, thereby effectuating tumor destruction in some cases. The attenuation of T cell activation by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) further limits the potency of tumor immunity. In murine systems, the administration of antibodies that block CTLA-4 function inhibits the growth of moderately immunogenic tumors and, in combination with cancer vaccines, increases the rejection of poorly immunogenic tumors, albeit with a loss of tolerance to normal differentiation antigens. To gain a preliminary assessment of the biologic activity of antagonizing CTLA-4 function in humans, we infused a CTLA-4 blocking antibody (MDX-CTLA4) into nine previously immunized advanced cancer patients. MDX-CTLA4 stimulated extensive tumor necrosis with lymphocyte and granulocyte infiltrates in three of three metastatic melanoma patients and the reduction or stabilization of CA-125 levels in two of two metastatic ovarian carcinoma patients previously vaccinated with irradiated, autologous granulocyte-macrophage colony-stimulating factor-secreting tumor cells. MDX-CTLA4 did not elicit tumor necrosis in four of four metastatic melanoma patients previously immunized with defined melanosomal antigens. No serious toxicities directly attributable to the antibody were observed, although five of seven melanoma patients developed T cell reactivity to normal melanocytes. These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients.

Abatacept↗
PubMed2002

Interventional radiology procedures in the liver. Biopsy, drainage, and ablation.

Radiologically guided interventional procedures in the liver have continually increased, in number and variety, over the years. Factors promoting these advances include new technology, innovative ideas, and growing acceptance by clinicians and patients. Percutaneous biopsy and drainage procedures are firmly established techniques with low complication rates. Ablation by injected substances is useful for treating certain tumor types. The most exciting development is the introduction of percutaneous thermal techniques for tumor ablation. Although more experience is needed to optimize the use of focal thermal ablation, early results seem promising.

Biopsy, Needle↗